Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4729 in Obesity
NCT07690826Phase 2Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-4729 in obesity (7 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Body Weight at 32 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HRS-4729
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07690826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690826.